Alternative Products Expo: Innovation and Sustainability

 Financial analysts, savvy investors, business owners, researchers, and pioneers, are invited to attend Alternative Products Expo to be held at the World Market Center, Las Vegas from September 14-16, 2023. Las Vegas plays host to thousands of esteemed events every year, and there are several reasons for this: state-of-the-art hospitality, top-notch facilities, year-round sunshine, and world-class dining and entertainment options. Featuring one-of-a-kind nightlife, the city never fails to provide a memorable experience for the attendees.

Alternative Products Expo (AltPro Expo) promises to deliver unique networking opportunities for customers and businesses alike. The highly anticipated event has earned a reputation for offering an incredible platform for business owners to showcase their unique and sustainable products. As the countdown for this innovative Expo begins, attendees can expect an unmatched experience packed with actionable insights from the industry leaders.

Exciting Opportunities for Forward-Thinking Businesses

Pioneered by a group of socially responsible entrepreneurs, the Alternative Products Expo is committed to connecting revolutionary businesses with health-conscious customers. The expo will feature a wide range of eco-friendly and innovative products, ranging from plant-based foods, and renewable energy technologies, to sustainable packaging solutions and ethical fashion items. They will witness innovative demos and learn of the latest product launches that will shape a sustainable future and reduce the environmental footprint at a global level.

The AltPro Expo provides customers with a unique opportunity to buy products that contribute to an eco-friendly planet. The organizers will implement sustainable practices throughout the Expo to ensure the targeted audience aligns with their values. Attendees will get a unique opportunity to network with like-minded entrepreneurs and potential investors who will share their passion for innovation. By attending thought-provoking seminars and panel discussions, they will get insights into the latest trends and best practices in the alternative products industry.

To learn more, please visit https://nnw.fm/mYVeW.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)waa
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

BREATHE! Convention 2023 – Connecting Ever-Expanding Possibilities

 BREATHE!, a historic new tech event that focuses on the emerging technologies that continue to revolutionize the way businesses and communication are conducted worldwide, is proud to announce this year’s BREATHE! Convention. The event, scheduled for September 13-15, 2023, at The Expo @ World Market Center Las Vegas, provides a platform for exhibiting, networking, and speaking opportunities, for individuals and organizations within the emerging tech ecosystem.

The event targets a diverse group of attendees, ranging from developers to investors, enthusiasts, and researchers, to discuss the latest developments and trends in emerging technologies while also exploring numerous collaborative and community-driven efforts. More than 5,000 attendees are anticipated to grace the event with more than 80 educators and subject matter experts expected to lead speaking seminars, fireside chats, and panel sessions. BREATHE! is designed to create opportunities encompassing education, experience, and entertainment, delivering a one-of-a-kind convention.

BREATHE! Convention’s vision encompasses some incredible and often unexplored aspects of the emerging tech industry, including:

• Identifying market trends
• Revolutionizing the industry
• Developing new use cases

These crucial aspects of the emerging tech industry are brought to light through a diverse array of speaking seminars, panel sessions, and fireside chats, where educators and subject matter experts deliver important insights and experiences on Web3, Blockchain, AI technologies and applications, and more. This community-driven lineup of educators also covers topics such as decentralized finance (“DeFi”), non-fungible tokens (“NFTs”), as well as the future of the Web3 ecosystem. The latest list of speakers is available for viewing at: https://www.breatheconvention.com/speakers-list

BREATHE! Convention’s vision is achieved through networking opportunities, with event spotting workshops, panel discussions, and networking mixers, all designed to help attendees connect and build relationships. In addition, attendees will see the latest emerging technologies and products in action in the exhibit hall, where attendees have access to live demonstrations of decentralized applications (“dApps”), smart contracts, blockchain-based games, and more.

BREATHE! Convention is one of the first ever emerging tech conventions approved by The Expo @ World Market Center Las Vegas, that has a prime focus on community, networking, and mass adoption of game-changing technology for professionals from all walks of life. Backed by passionate, community-involved investors and collaborators, and built on education, experience, and entertainment through the power of emerging tech, this event lives true to its core narrative: “Connecting Ever-Expanding Possibilities.”

BREATHE! Convention is powered by Metakeep and NFT-TiX

To learn more, please visit https://nnw.fm/74×77

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)waa
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

GolfLync Inc., Looking Remarkably Like an Early-Stage Unicorn

 

• GolfLync has tapped and fulfills a confirmed need in a strong market, like the most successful fast-growing companies that have come before it
• GolfLync does a superior job of engaging and bringing together the expanding golf community, using intelligent technology with a user-friendly interface
• Remarkable membership growth, a far above average conversion rate, and high social media ratings, point to a unique opportunity for investors as well as golf lovers

Usually defined as a startup that is privately owned with a valuation that exceeds $1 billion, a unicorn is the epitome of spectacular growth. Although being a unicorn doesn’t guarantee permanent success, the most famous former unicorns, such as Google (NASDAQ: GOOGL), Facebook (NASDAQ: META), and Airbnb (NASDAQ: ABNB), now have astronomical market caps, with Google’s topping out at over $1.5 trillion. Every one of them started out small, but with an idea that filled a real need, fueling rapid growth and investment. In particular, social media apps that empower the building of specialized online communities can soar on word-of-mouth alone.

GolfLync is soaring due to its unique and feature-strong ability to bring together people who love golf, a sport that is experiencing a post-pandemic revival, and a market that was already listed at $26.1 billion in 2022 (26 Glorious Golf Industry Statistics [2023]: How Big Is The Golf Industry – Zippia). The app (available as a free download on the Apple App Store and the Google Play Store) is powered by an intelligent algorithm that brings golfers together based upon a balanced range of factors, including handicap, preferred playing style, and location, along with various related interests and specifications. The app readily supports everything from matching individual partners to building large and diverse groups called “Virtual Golf Clubs”(TM). These GolfLync VGCs are becoming especially popular, and now spread around the country.

GolfLync CEO Noah DiPasquale says “It basically operates like Tinder for golfers”, while Michael Quiel, Co-Founder, summed it up: “Our commitment to providing a user-friendly and feature-rich platform has driven the exceptional growth and engagement we are witnessing.” According to the company, GolfLync has seen a 15x growth in membership in just the past 4 months. In addition, GolfLync has a social media conversion rate greater than 52%, compared to the average conversion rate of less than 33%, and has now reached the 75th percentile for user conversions as shown in the Apple Store. The GolfLync platform currently exceeds 200 ratings on the Apple App store with 5-star average.

You can download the GolfLync app using the following links:

• Android: GolfLync – Apps on Google Play 
• iPhone: ‎GolfLync

For more information about GolfLync, visit the company’s website at www.GolfLync.com.

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://nnw.fm/GOLF

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)waa
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation Amid Preparations for Planned Acclaim-3 Clinical Trial

 

• Genprex recently received orphan drug designation for its lead drug candidate REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid) for the treatment of small cell lung cancer (“SCLC”)
• The company also celebrated receipt of its third Fast Track Designation (“FTD”), granted by the FDA, this time for REQORSA Immunogene Therapy, in combination with Tecentriq in patients with extensive stage small cell lung cancer (“ES-SCLC”)
• The orphan drug designation (“ODD”) in combination with the FTD is an indication of the great need for better treatment options for patients with ES-SCLC, and non-small cell lung cancer (“NSCLC”), according to Genprex President, Chairman, and CEO Rodney Varner
• With the receipt of the latest FTD and the orphan drug status, Genprex is looking forward to initiating the Acclaim-3 clinical trial, planned for the fourth quarter of 2023

Genprex (NASDAQ: GNPX), a clinical-stage company developing life-changing gene therapies for patients with cancer and diabetes, recently celebrated an important milestone: the award of an orphan drug designation. The company announced August 10 that the United States Food and Drug Administration (“FDA”) had granted Orphan Drug Designation (“ODD”) to its lead drug candidate, REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid), for the treatment of small cell lung cancer (“SCLC”) (https://nnw.fm/veZJi).

The FDA grants orphan drug status to a drug or biological product that prevents, diagnoses, or treats a rare disease or condition as part of the agency’s efforts to prioritize the development and evaluation of new treatments for rare diseases (https://nnw.fm/tA8Gk). The ODD grants a sponsor – in this case, Genprex – incentives such as tax credits for qualified clinical trials and an exemption from user fees. Perhaps most importantly, the orphan drug designation grants potential seven-year exclusivity post-approval. The global SCLC therapeutics market is projected to grow at a CAGR of 12.3% from $5.12 billion in 2022 to $16.33 billion by 2032 (https://nnw.fm/nX6u9).

The Orphan Drug Act (“ODA”) of 1983 defines rare diseases as those affecting “less than 200,000 persons in the United States.”  The FDA interprets this to mean that the prevalence of the disease, that is the number of people affected by the disease at a particular point in time, must be less than 200,000.  This is different than the incidence of the disease, which is the number of people newly diagnosed with SCLC during the course of a year (https://nnw.fm/H64KC).

Based on the orphan drug definition SCLC is classified as a rare disease because the prevalence of SCLC is less than 200,000 cases in the US. The condition accounts for 13-15% of all lung cancer cases, and in the United States, about 238,440 adults will be diagnosed with lung cancer in 2023. The condition also presents a poor prognosis, partly because a majority of people – more than 60% – with SCLC are diagnosed after the cancer has spread outside the lung (https://nnw.fm/7GwlY). In such cases, the condition is known as extensive-stage SCLC (“ES-SCLC”).

Patients with ES-SCLC are given combination chemotherapy as the first-line treatment, with varying overall response rates of 44-78% and median progression-free survival (“mPFS”) that ranges between 4.3 and 5.7 months, depending on the selected combination (https://nnw.fm/lvC4J). Patients also undergo maintenance therapy, an ongoing cancer treatment, after the initial response to the first recommended treatment. The mPFS for patients receiving Genentech, Inc.’s Tecentriq(R) as maintenance treatment is only 2.6 months from the start of maintenance treatment, suggesting a substantial need for improvement in maintenance therapy, according to Genprex.

Genprex’s efforts to meet this need received a boost in June 2023 when the FDA granted Fast Track Designation (“FTD”) for REQORSA Immunogene Therapy, in combination with Tecentriq in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment (https://nnw.fm/9m5VN).

“We are excited to receive Orphan Drug Designation from the FDA for REQORSA for patients with SCLC,” commented Rodney Varner, President, Chairman, and CEO of Genprex. “This FDA Orphan Drug Designation in combination with our recently received FDA Fast Track Designation underscores the great need for better treatment options for patients with SCLC, ES-SCLC, and non-small cell lung cancer.”

Genprex’s lung cancer programs now have three FDA Fast Track Designations. In January 2020, the company announced that the FDA had granted an FTD for REQORSA in combination with AstraZeneca’s Tagrisso(R) for patients with NSCLC whose condition progressed after treatment with Tagrisso (https://nnw.fm/GMLVy). Later, in January 2022, the company announced it had received an FTD for REQORSA Immunogene Therapy in combination with Merck & Company’s Keytruda(R) in patients with NSCLC whose disease progressed after treatment with Keytruda (https://nnw.fm/fZOOJ). 

With the receipt of the latest FTD and the orphan drug status, Genprex is looking forward to initiating the Acclaim-3 clinical trial, expected in the fourth quarter of 2023. Acclaim-3 is a Phase 1/2 open-label, dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)waa
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork